Technical Analysis for ELOX - Eloxx Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 6.26 0.32% 0.02
ELOX closed up 0.32 percent on Monday, August 19, 2019, on 39 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ELOX trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Up 3 Days in a Row Strength 0.00%
Inside Day Range Contraction 0.32%
Wide Bands Range Expansion 0.32%
Doji - Bullish? Reversal 1.29%
Wide Bands Range Expansion 1.29%
New 52 Week Closing Low Bearish 3.64%
180 Bearish Setup Bearish Swing Setup 3.64%
Wide Bands Range Expansion 3.64%
1,2,3 Retracement Bearish Bearish Swing Setup -4.86%

Older signals for ELOX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Eloxx Pharmaceuticals, Inc. (ELOX) is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.
Biopharmaceutical Biology Molecular Biology Genetics Gene Expression Cystic Fibrosis Genetic Diseases Molecular Genetics Messenger RNA Genetic Code Protein Biosynthesis Rare And Ultra Rare Diseases
Is ELOX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 18.5
52 Week Low 5.14
Average Volume 96,419
200-Day Moving Average 11.2892
50-Day Moving Average 8.4878
20-Day Moving Average 7.0865
10-Day Moving Average 6.341
Average True Range 0.652
ADX 36.06
+DI 10.839
-DI 27.9297
Chandelier Exit (Long, 3 ATRs ) 7.184000000000001
Chandelier Exit (Short, 3 ATRs ) 7.096
Upper Bollinger Band 8.6744
Lower Bollinger Band 5.4986
Percent B (%b) 0.24
BandWidth 44.814789
MACD Line -0.7225
MACD Signal Line -0.7061
MACD Histogram -0.0164
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.01
Resistance 3 (R3) 7.01 6.75 6.88
Resistance 2 (R2) 6.75 6.56 6.75 6.84
Resistance 1 (R1) 6.51 6.44 6.38 6.51 6.80
Pivot Point 6.25 6.25 6.19 6.25 6.25
Support 1 (S1) 6.01 6.06 5.88 6.01 5.72
Support 2 (S2) 5.75 5.94 5.76 5.68
Support 3 (S3) 5.51 5.75 5.64
Support 4 (S4) 5.51